Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB reports encouraging Phase III data for lacosamide
With a standard titration regimen, the trial met its primary objective with sustained and statistically significant reduction in average daily pain scores. The trial in 551 patients with
With a standard titration regimen, the trial met its primary objective with sustained and statistically significant reduction in average daily pain scores. The trial in 551 patients with
The acquisition is expected to be implemented by way of a court approved scheme of arrangement, whereby BBI would become a wholly owned subsidiary of Inverness Medical. The
The Valeo implant is intended for vertebral body replacement to aid in surgical correction and stabilization of the thoracolumbar spine. The company said that Valeo VBR incorporates its
Under the terms of the agreement, the first phase of the partnership will commence immediately, and will include the commercialization and exporting of existing Organogenesis technology, including its
The program includes a set of four trials evaluating a variety of obesity-related outcome measures, which together are expected to support the new drug application for approval of
The manager of the drugs control department said that importation of Oral-lyn can be done via the issuance of a purchase order from the Imperial College London Diabetes
A range of active compounds are protected, each related to the active ingredient in PV-10. Provectus is currently conducting Phase II clinical trials of its proprietary drugs PV-10
Daniel Carr, CEO and CMO of Javelin, said: “Today is a watershed in Javelin’s evolution from a development company to a revenue-generating organization. Pricing publication marks the UK
The completion of the sale of the assets will launch effectively Ore Pharmaceuticals as a new company focused on drug repositioning and development. Ownership of the name Gene
The primary objectives of this Phase Ia study were to characterize the safety, tolerability and pharmacokinetics of a single dose of IL-29 administered subcutaneously. A total of 20